

日本血液学会造血器腫瘍診療ガイドライン
(2023 年版)【英語版】

2025 年掲載

1. Takahashi N, Takenaka K, Iriyama N, Kirito K, Kawaguchi T, Kimura S, et al. JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol. 2025;121:5–38.
<https://link.springer.com/article/10.1007/s12185-024-03865-2>
2. Takamatsu Y. JSH practical guidelines for hematological malignancies, 2023: leukemia-5. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Int J Hematol. 2025;121:432–49.
<https://link.springer.com/article/10.1007/s12185-025-03914-4>
3. Miyazaki Y. JSH practical guidelines for hematological malignancies, 2023: leukemia-6. Myelodysplastic syndromes (MDS). Int J Hematol. 2025;121: 294–317.
<https://link.springer.com/article/10.1007/s12185-024-03906-w>
4. Ohmachi, K. JSH practical guidelines for hematological malignancies, 2023: II. lymphoma—overview Int J Hematol. 2025;121:567–76.
<https://link.springer.com/article/10.1007/s12185-025-03920-6>

5. Yoshida I. JSH Practical Guidelines for Hematological Malignancies, 2023: II. Lymphoma—2. Marginal zone lymphoma: MZL (extranodal marginal zone lymphoma: EMZL [extranodal marginal zone lymphoma of mucosa associated lymphoid tissue], nodal marginal zone lymphoma: NMZL, splenic marginal zone lymphoma: SMZL) Int J Hematol. 2025;121:725–39.
<https://link.springer.com/article/10.1007/s12185-025-03947-9>
6. Yoshida I. JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma3. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM) Int J Hematol. 2025;121:740–5.
<https://link.springer.com/article/10.1007/s12185-025-03948-8>
7. Ishizawa K, Yamamoto K. JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 4. Mantle cell lymphoma (MCL) Int J Hematol. 2025;121:746–55.
<https://link.springer.com/article/10.1007/s12185-025-03960-y>
8. Ohmachi K. JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) Int J Hematol. 2025;122:3–16.
<https://link.springer.com/article/10.1007/s12185-025-03997-z>
9. Nishikori M, Kondo Eisei. JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 6. Burkitt lymphoma/high-grade B-cell lymphoma (BL/HGBL) Int J Hematol. 2025;122:17–24.
<https://link.springer.com/article/10.1007/s12185-025-03982-6>

10. Maruyama D, Yoshimitsu M. JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 7. Peripheral T-cell lymphoma (PTCL) Int J Hematol. 2025;122:165–171.
<https://link.springer.com/article/10.1007/s12185-025-04018-9>
11. Maruyama D, Yoshimitsu M. JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 8. Extranodal NK/T-cell lymphoma, nasal type (ENKL) Int J Hematol. 2025;122:172–6.
<https://link.springer.com/article/10.1007/s12185-025-04019-8>
12. Nosaka K, Fukushima T. JSH practical guidelines for hematological malignancies, 2023: II. lymphoma 9—adult T-cell leukemia–lymphoma (ATL) Int J Hematol. 2025;122:77–189.
<https://link.springer.com/article/10.1007/s12185-025-04011-2>
13. Iida S, Ito S, Sunami K, Takamatsu H, Tsukada N, Hosen N, et al. JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 1. Multiple myeloma (MM) Int J Hematol. 2025;122:465–509.
<https://link.springer.com/article/10.1007/s12185-025-04045-6>
14. Iida S, Ito S, Sunami K, Takamatsu H, Tsukada N, Hosen N, et al. JSH practical guidelines for hematological malignancies, 2023 III. Myeloma 2. Related disorders of multiple myeloma Int J Hematol. 2025;122:510–20.
<https://link.springer.com/article/10.1007/s12185-025-04051-8>

*****2024 年掲載*****

15. Maeda Y. JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML). Int J Hematol. 2024;119:347–73.
<https://link.springer.com/article/10.1007/s12185-024-03730-2>
16. Fujita H. JSH practical guidelines for hematological malignancies, 2023: leukemia-2—acute promyelocytic leukemia (APL). Int J Hematol. 2024;119:481–92.
<https://link.springer.com/article/10.1007/s12185-024-03749-5>
17. Hatta Y, Izutsu K, Onizuka M, Dobashi N, Hayakawa F, Yamazaki E. JSH practical guidelines for hematological malignancies, 2023: leukemia-3. Acute lymphoblastic leukemia/lymphoblastic lymphoma: ALL/LBL. Int J Hematol. 2024;120:394–413.
<https://link.springer.com/article/10.1007/s12185-024-03836-7>
18. Takahashi N, Takenaka K, Iriyama N, Kirito K, Kawaguchi T, Kimura S, et al. JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol. 2025;121:5–38.
<https://link.springer.com/article/10.1007/s12185-024-03865-2>
19. Takamatsu Y. JSH practical guidelines for hematological malignancies, 2023: leukemia-5. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Int J Hematol. 2025;121:432–49.
<https://link.springer.com/article/10.1007/s12185-025-03914-4>

20. Miyazaki Y. JSH practical guidelines for hematological malignancies, 2023: leukemia-6. Myelodysplastic syndromes (MDS). *Int J Hematol.* 2025;121: 294–317.
<https://link.springer.com/article/10.1007/s12185-024-03906-w>
21. Ohmachi, K. JSH practical guidelines for hematological malignancies, 2023: II. lymphoma—overview *Int J Hematol.* 2025;121:567–576.
<https://link.springer.com/article/10.1007/s12185-025-03920-6>